(Version française à venir...)
This new team will focus on discovering and developing predictive and prognostic biomarkers for personalized management in GI oncology. The team includes full time researchers working on basic and translational aspects, as well as clinicians and aims at developing integrative and clinically-relevant GI cancer research. Our project leans on a variety of interdisciplinary skills in basic research of signaling pathways, molecular biology and pathology, tumor microenvironment, pharmacokinetics, imaging biomarkers, biostatistics and clinical research. Research works will involve basic and applied researchers as well as clinicians to develop innovative translational GI cancer research programs. Specifically, we are interested in the analysis of circulating cell free DNA and miRNA, protein dimerization profiles, wnt/β-Catenin oncogenic signaling pathways, pharmacokinetic and pharmacodynamic models applied to cytotoxic/targeted agents and their metabolites, novel imaging predictors. An additional asset will be the integration of biostatistics methodological research for biomarkers evaluation. Special emphasis will be directed towards the expression of new molecular and genetic markers on human tumor/tissue samples.
In line with the colorectal cancer research program conducted through the Integrated Cancer Research Site “SIRIC Montpellier Cancer”, our plan is to establish new ties between basic research and clinical needs to achieve significant and practice-changing advances in GI cancer research.
A.R. Thierry, S. El Messaoudi, C. Mollevi, J.L. Raoul, R. Guimbaud, D. Pezet, P. Artru, E. Assenat, C. Borg, M. Mathonnet. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
Parseghian C, Parikh NU, Wu JY, Jiang ZQ, Henderson LD, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman D, Katsiampoura A, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Mar 9. pii: clincanres.3138.2016. doi: 10.1158/1078-0432.CCR-16-3138. [Epub ahead of print]
Alain R. Thierry, Brice Pastor, Zhi-Qin Jiang, Anastasia Katsiampoura, Christine Parseghian, Jonathan M. Loree, Michael J. Overman, Cynthia Sanchez, Safia El Messaoudi, Marc Ychou and Scott Kopetz. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clinical Cancer Research, 10.1158/1078-0432.CCR-17-0232
Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L. Population pharmacokinetics of gemcitabine and dFdU in pancreatic cancer patients using an optimal design, sparse sampling approach. Ther Drug Monit. 2017 Mar 24. doi: 10.1097/FTD.399. [Epub ahead of print] PubMed PMID: 28346313.
Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017 Mar 8;76:68-75. doi: 10.1016/j.ejca.2017.02.003. [Epub ahead of print]